On December 21, 2012, Transcept Pharmaceuticals, Inc. issued a press release announcing initial top-line results from its Phase 2 clinical trial evaluating TO-2061 in patients with obsessive compulsive disorder who had not adequately responded to treatment with approved first-line therapies.

A copy of the press release, dated December 21, 2012, is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The following Exhibit is filed as part of this Current Report on Form 8-K.

(d) Exhibits

Exhibit
Number                                    Description

99.1         Press Release, "Transcept Pharmaceuticals Announces that a Phase 2
             Clinical Trial of TO-2061 as Adjunctive Therapy for Obsessive
             Compulsive Disorder Did Not Meet Primary Endpoint" dated December 21,
             2012.